CN104487430B - 用于制造羟基化的环戊基嘧啶化合物的方法 - Google Patents

用于制造羟基化的环戊基嘧啶化合物的方法 Download PDF

Info

Publication number
CN104487430B
CN104487430B CN201380037994.8A CN201380037994A CN104487430B CN 104487430 B CN104487430 B CN 104487430B CN 201380037994 A CN201380037994 A CN 201380037994A CN 104487430 B CN104487430 B CN 104487430B
Authority
CN
China
Prior art keywords
formula
compound
salt
catalyst
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380037994.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104487430A (zh
Inventor
J·W·莱恩
T·雷马查克
S·谢克亚
K·L·斯潘瑟
P·J·斯腾格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CN104487430A publication Critical patent/CN104487430A/zh
Application granted granted Critical
Publication of CN104487430B publication Critical patent/CN104487430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380037994.8A 2012-05-17 2013-05-17 用于制造羟基化的环戊基嘧啶化合物的方法 Active CN104487430B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US61/648,421 2012-05-17
US201361785281P 2013-03-14 2013-03-14
US61/785,281 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
CN104487430A CN104487430A (zh) 2015-04-01
CN104487430B true CN104487430B (zh) 2016-08-24

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037994.8A Active CN104487430B (zh) 2012-05-17 2013-05-17 用于制造羟基化的环戊基嘧啶化合物的方法

Country Status (18)

Country Link
US (1) US9309204B2 (enExample)
EP (1) EP2861583B1 (enExample)
JP (1) JP6214636B2 (enExample)
KR (1) KR20150020211A (enExample)
CN (1) CN104487430B (enExample)
AU (1) AU2013262568B2 (enExample)
BR (1) BR112014028570A2 (enExample)
CA (1) CA2873653A1 (enExample)
DK (1) DK2861583T3 (enExample)
ES (1) ES2588878T3 (enExample)
IL (1) IL235714A0 (enExample)
MA (1) MA37649B1 (enExample)
MX (1) MX2014013865A (enExample)
PL (1) PL2861583T3 (enExample)
RU (1) RU2014151017A (enExample)
SG (1) SG11201407613RA (enExample)
SI (1) SI2861583T1 (enExample)
WO (1) WO2013173736A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
CN112898210B (zh) 2013-11-15 2025-02-21 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
KR102284944B1 (ko) * 2013-11-27 2021-08-03 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
PL3197875T3 (pl) * 2014-09-26 2020-03-31 F. Hoffmann-La Roche Ag Sposoby wytwarzania związków (cyklopentylo[d]pirymidyn-4-ylo)piperazynowych
CN120887837A (zh) 2020-06-16 2025-11-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188754A1 (en) * 1999-06-03 2002-03-20 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101918373A (zh) * 2007-07-05 2010-12-15 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CN101932564A (zh) * 2008-01-09 2010-12-29 阵列生物制药公司 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷类

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
BR112012011328A2 (pt) 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188754A1 (en) * 1999-06-03 2002-03-20 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101918373A (zh) * 2007-07-05 2010-12-15 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CN101932564A (zh) * 2008-01-09 2010-12-29 阵列生物制药公司 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷类

Also Published As

Publication number Publication date
JP6214636B2 (ja) 2017-10-18
EP2861583B1 (en) 2016-06-29
PL2861583T3 (pl) 2016-12-30
SI2861583T1 (sl) 2016-10-28
AU2013262568B2 (en) 2017-08-31
EP2861583A1 (en) 2015-04-22
MX2014013865A (es) 2015-05-07
ES2588878T3 (es) 2016-11-07
RU2014151017A (ru) 2016-07-10
AU2013262568A1 (en) 2015-01-22
US9309204B2 (en) 2016-04-12
BR112014028570A2 (pt) 2018-04-24
IL235714A0 (en) 2015-02-01
US20150099881A1 (en) 2015-04-09
MA37649B1 (fr) 2017-03-31
KR20150020211A (ko) 2015-02-25
DK2861583T3 (en) 2016-10-03
WO2013173736A1 (en) 2013-11-21
SG11201407613RA (en) 2015-01-29
JP2015518837A (ja) 2015-07-06
CN104487430A (zh) 2015-04-01
HK1208673A1 (en) 2016-03-11
CA2873653A1 (en) 2013-11-21
MA37649A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
CN104487430A (zh) 用于制造羟基化的环戊基嘧啶化合物的方法
CN104471070B (zh) 制备羟基化环戊并嘧啶化合物和其盐的方法
KR102067850B1 (ko) 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법
KR102074535B1 (ko) 아미노산 화합물의 제조 방법
EP3626710B1 (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208673B (en) Process for making hydroxylated cyclopentylpyrimidine compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208857B (en) Process for making amino acid compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208673

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208673

Country of ref document: HK